Characterization of associations and development of atazanavir resistance after unplanned treatment interruptions1. Issue 4 (12th November 2013)

• Record Type: Journal Article
• Authors: Tinago, W; O'Halloran, JA; O'Halloran, RM; Macken, A; Lambert, JS; Sheehan, GJ; Mallon, PWG
• Is Part Of: HIV medicine. Volume 15:Issue 4(2014:Apr.)
• Page Start: 224
• Page End: 232
• Publication Date: 2013-11-12
• Subjects: HIV infections -- Treatment -- Periodicals; HIV-positive persons -- Periodicals; HIV infections -- Treatment -- Decision making -- Periodicals; 616.9792
• DOI: 10.1111/hiv.12107
• Languages: English
• ISSNs: 1464-2662

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="hiv12107-sec-0012" sec-type="section"> <title>Objectives</title> <p>Although current guidelines recommend resistance testing prior to antiretroviral therapy (ART) reinitiation after treatment interruptions, virological failure of first‐line ritonavir‐boosted, protease‐inhibitor (PI/r)‐containing ART is associated with low emergent PI resistance. In patients experiencing unscheduled treatment interruptions (UTrIs) on ritonavir‐boosted atazanavir (ATV/r) ART regimens, we hypothesized low emergence of PI mutations conferring resistance to ATV/r.</p> </sec> <sec id="hiv12107-sec-0013" sec-type="section"> <title>Methods</title> <p>In a retrospective assessment of HIV‐infected patients initiating ATV/r‐containing ART, using logistic regression we determined factors associated with UTrI, the prevalence of emergent resistance mutations and virological response after ART reinitiation.</p> </sec> <sec id="hiv12107-sec-0014" sec-type="section"> <title>Results</title> <p>A total of 202 patients [median age 33 years (interquartile range (IQR) 29–40 years); 52% female; median CD4 count 184 cells/μL (IQR 107–280 cells/μL); median HIV RNA 4.6 log<sub>10</sub> HIV‐1 RNA copies/mL (IQR 3.2–5.1 copies/mL)] initiated ATV/r between 2004 and 2009; 80 (43%) were ART naïve. One hundred and ten patients (55%) underwent 195 UTrIs after a median (IQR) 25 (10–52) weeks on ART, with a median (IQR) UTrI duration of 10 (3–31) weeks. Fifty‐four of 110 patients (49%) underwent more than one UTrI. The commonest reasons for UTrI were nonadherence (52.7%) and drug intolerance (20%). Baseline HIV RNA > 100 000 copies\mL [odds ratio (OR) 3.6; 95% confidence interval (CI) 1.3–9.95] and being HCV positive, an injecting drug user or on methadone (OR 2.4; 95% CI 1.3–4.4) were independently associated with UTrI. In 39 patients with at least two resistance assays during UTrIs, 72 new mutations emerged; four nucleoside reverse transcriptase inhibitor (NRTI), two nonnucleoside reverse transcriptase inhibitor (NNRTI) and 66 protease inhibitor (PI) resistance mutations. All emergent PI resistance mutations were minor mutations. At least 65% of patients were re‐suppressed on ATV/r reinitiation.</p> </sec> <sec id="hiv12107-sec-0015" sec-type="section"> <title>Conclusions</title> <p>In this PI‐treated cohort, UTrIs are common. All emergent PI resistance mutations were minor and ATV/r retained activity and efficacy when reintroduced, even after several UTrIs, raising questions regarding the need for routine genotypic resistance assays in PI/r‐treated patients prior to ART reinitiation after UTrI.</p> </sec> </abstract>